Vamil Divan
Stock Analyst at Guggenheim
(4.87)
# 62
Out of 5,156 analysts
248
Total ratings
70.39%
Success rate
21.43%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Buy | $122 → $140 | $117.11 | +19.55% | 15 | Feb 6, 2026 | |
| AMGN Amgen | Maintains: Neutral | $305 → $347 | $376.97 | -7.95% | 2 | Feb 6, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $227 → $240 | $242.59 | -1.07% | 19 | Jan 23, 2026 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $115 → $124 | $74.81 | +65.75% | 14 | Jan 16, 2026 | |
| INSM Insmed | Maintains: Buy | $230 → $221 | $143.13 | +54.41% | 8 | Dec 18, 2025 | |
| PFE Pfizer | Maintains: Buy | $33 → $35 | $26.81 | +30.55% | 23 | Nov 24, 2025 | |
| JBIO Jade Biosciences | Maintains: Buy | $14 → $17 | $14.43 | +17.81% | 2 | Nov 18, 2025 | |
| ELDN Eledon Pharmaceuticals | Maintains: Buy | $9 → $8 | $2.90 | +175.86% | 1 | Nov 18, 2025 | |
| SCYX SCYNEXIS | Maintains: Buy | $4 → $3 | $0.86 | +248.84% | 3 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Buy | $227 → $242 | $227.45 | +6.40% | 28 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $11 | $5.43 | +102.58% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $13 | $10.50 | +23.81% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $39 | $29.12 | +33.93% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $2.39 | +192.89% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $7.05 | +751.06% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $28.98 | +62.18% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.51 | +298.41% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $38.97 | +56.53% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $11.35 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $7.17 | +262.62% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.56 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $22.58 | -15.85% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $129.93 | -24.57% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $28.45 | +19.51% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.27 | +205.81% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $164.49 | -70.21% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $1,008.39 | -64.70% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $5.60 | +7.14% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $10.21 | +1,408.33% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $5.35 | +180.37% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $33.06 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $31.50 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $15.89 | -5.60% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $60.63 | +0.61% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $3.04 | +3,288.16% | 3 | Jan 17, 2018 |
Merck & Co.
Feb 6, 2026
Maintains: Buy
Price Target: $122 → $140
Current: $117.11
Upside: +19.55%
Amgen
Feb 6, 2026
Maintains: Neutral
Price Target: $305 → $347
Current: $376.97
Upside: -7.95%
Johnson & Johnson
Jan 23, 2026
Maintains: Buy
Price Target: $227 → $240
Current: $242.59
Upside: -1.07%
ANI Pharmaceuticals
Jan 16, 2026
Maintains: Buy
Price Target: $115 → $124
Current: $74.81
Upside: +65.75%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $230 → $221
Current: $143.13
Upside: +54.41%
Pfizer
Nov 24, 2025
Maintains: Buy
Price Target: $33 → $35
Current: $26.81
Upside: +30.55%
Jade Biosciences
Nov 18, 2025
Maintains: Buy
Price Target: $14 → $17
Current: $14.43
Upside: +17.81%
Eledon Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.90
Upside: +175.86%
SCYNEXIS
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.86
Upside: +248.84%
AbbVie
Oct 20, 2025
Maintains: Buy
Price Target: $227 → $242
Current: $227.45
Upside: +6.40%
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $5.43
Upside: +102.58%
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $10.50
Upside: +23.81%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $29.12
Upside: +33.93%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.39
Upside: +192.89%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $7.05
Upside: +751.06%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $28.98
Upside: +62.18%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.51
Upside: +298.41%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $38.97
Upside: +56.53%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $11.35
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $7.17
Upside: +262.62%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.56
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $22.58
Upside: -15.85%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $129.93
Upside: -24.57%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $28.45
Upside: +19.51%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $3.27
Upside: +205.81%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $164.49
Upside: -70.21%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $1,008.39
Upside: -64.70%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $5.60
Upside: +7.14%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $10.21
Upside: +1,408.33%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $5.35
Upside: +180.37%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $33.06
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $31.50
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $15.89
Upside: -5.60%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $60.63
Upside: +0.61%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $3.04
Upside: +3,288.16%